Correction to: Pain Ther https://doi.org/10.1007/s40122-019-0118-0
Under section “Introduction”, the first sentence in the 4th paragraph was incorrectly published. The correct sentence is given below.
Prior usability research found that no untrained, and about 60% of trained, users were able to successfully administer a full dose of naloxone using a PFS-NA [11], whereas > 90% of untrained users were able to successfully administer a full dose using NARCAN® Nasal Spray [12].
The original article has been corrected.
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Tippey, K.G., Yovanoff, M., McGrath, L.S. et al. Correction to: Comparative Human Factors Evaluation of Two Nasal Naloxone Administration Devices: NARCAN® Nasal Spray and Naloxone Prefilled Syringe with Nasal Atomizer. Pain Ther 8, 99 (2019). https://doi.org/10.1007/s40122-019-0123-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40122-019-0123-3